Jeffrey A. Engelman

Jeffrey A. Engelman's AcademicInfluence.com Rankings

Jeffrey A. Engelman

Philosophy

#4436

World Rank

#6947

Historical Rank

Logic

#1886

World Rank

#2751

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jeffrey A. Engelman's Degrees

PhD Biological Sciences Stanford University
Doctorate Medicine Stanford University

Why Is Jeffrey A. Engelman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jeffrey A. Engelman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007) (3564)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. (2010) (3445)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2011) (3017)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism (2006) (2993)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations (2009) (2289)
Systematic identification of genomic markers of drug sensitivity in cancer cells (2012) (2134)
Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers (2008) (1294)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers (2012) (1212)
The PI3K pathway as drug target in human cancer. (2010) (1199)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. (2012) (1194)
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. (2001) (1177)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (2016) (1064)
Caveolins, Liquid-Ordered Domains, and Signal Transduction (1999) (1055)
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. (2010) (981)
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer (2008) (923)
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway (2017) (911)
Ceritinib in ALK-rearranged non-small-cell lung cancer. (2014) (875)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (2011) (875)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis (2016) (845)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. (2008) (845)
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. (2012) (798)
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. (2014) (754)
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (2010) (734)
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. (2014) (697)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition (2016) (677)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. (2007) (677)
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer (2008) (671)
Anchored multiplex PCR for targeted next-generation sequencing (2014) (654)
Prospects for combining targeted and conventional cancer therapy with immunotherapy (2017) (650)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer (2014) (627)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. (2015) (618)
ROS1 rearrangements define a unique molecular class of lung cancers. (2012) (617)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab (2011) (577)
Targeting the PI3K signaling pathway in cancer. (2010) (549)
Ceritinib in ALK-rearranged non-small-cell lung cancer. (2014) (543)
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. (2008) (540)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK (2011) (540)
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. (2005) (527)
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network (2007) (510)
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. (2005) (492)
Targeted downregulation of caveolin‐1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade (1998) (485)
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer (2013) (478)
Cell-type and Tissue-specific Expression of Caveolin-2 (1997) (477)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. (2006) (461)
Caveolin-3 Null Mice Show a Loss of Caveolae, Changes in the Microdomain Distribution of the Dystrophin-Glycoprotein Complex, and T-tubule Abnormalities* (2001) (456)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer (2016) (453)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) (448)
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response (2012) (439)
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. (2015) (437)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 (2012) (421)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. (2016) (421)
Caveolin‐mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo (1998) (410)
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. (2015) (403)
Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. (2005) (402)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. (2016) (401)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies (2015) (397)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine (2010) (391)
Recombinant Expression of Caveolin-1 in Oncogenically Transformed Cells Abrogates Anchorage-independent Growth* (1997) (386)
ALK in lung cancer: past, present, and future. (2013) (385)
Specific Inhibitors of p38 Mitogen-activated Protein Kinase Block 3T3-L1 Adipogenesis* (1998) (378)
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers (2011) (366)
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. (2011) (365)
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. (2014) (359)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. (2011) (353)
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation (2010) (350)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (342)
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. (2013) (342)
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. (2010) (339)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia (2018) (327)
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. (2009) (325)
A combinatorial strategy for treating KRAS mutant lung cancer (2016) (313)
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses (2015) (312)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy. (2008) (309)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition (2009) (300)
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. (2012) (300)
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer (2013) (298)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance (2009) (297)
Acquired resistance to crizotinib from a mutation in CD74-ROS1. (2013) (292)
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. (2010) (282)
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. (2011) (276)
Tyrosine kinase gene rearrangements in epithelial malignancies (2013) (273)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib (2014) (259)
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. (2005) (254)
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. (2010) (244)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. (2015) (239)
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. (2005) (231)
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. (2010) (230)
Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers (1998) (229)
Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo (1998) (224)
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer (2013) (222)
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor (2010) (220)
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. (2007) (219)
Expression of Caveolin-1 Is Required for the Transport of Caveolin-2 to the Plasma Membrane (1999) (218)
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. (2011) (203)
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. (2011) (202)
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. (2013) (194)
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). (2011) (190)
Phosphoinositide 3-Kinase Catalytic Subunit Deletion and Regulatory Subunit Deletion Have Opposite Effects on Insulin Sensitivity in Mice (2005) (184)
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. (2018) (184)
Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is up-regulated in response to cell injury. (1998) (180)
Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. (1998) (179)
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 (2013) (179)
p42/44 MAP Kinase-dependent and -independent Signaling Pathways Regulate Caveolin-1 Gene Expression (1999) (178)
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors (2011) (177)
Crowded little caves: structure and function of caveolae. (1998) (174)
SnapShot: non-small cell lung cancer. (2012) (173)
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer (2014) (170)
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib (2015) (168)
FGFR1 Amplification in Squamous Cell Carcinoma of The Lung (2012) (167)
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. (2014) (167)
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. (2015) (164)
Sequence and detailed organization of the human caveolin‐1 and ‐2 genes located near the D7S522 locus (7q31.1) (1999) (155)
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex (2005) (152)
A functional landscape of resistance to ALK inhibition in lung cancer. (2015) (151)
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. (2012) (146)
Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3) (1998) (143)
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations (2005) (142)
Targeted Down-regulation of Caveolin-3 Is Sufficient to Inhibit Myotube Formation in Differentiating C2C12 Myoblasts (1999) (142)
Gene-target recognition among members of the Myc superfamily and implications for oncogenesis (2000) (140)
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors (2018) (134)
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib (2014) (133)
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases (2012) (133)
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma (2013) (131)
Mutational analysis of caveolin‐induced vesicle formation (1998) (131)
Palmitoylation of Caveolin-1 at a Single Site (Cys-156) Controls Its Coupling to the c-Src Tyrosine Kinase (2001) (128)
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping (2016) (127)
Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (126)
Tumor Necrosis Factor α-Mediated Insulin Resistance, but Not Dedifferentiation, Is Abrogated by MEK1/2 Inhibitors in 3T3-L1 Adipocytes (2000) (125)
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. (2011) (124)
Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers (2011) (124)
Genetic Changes in Squamous Cell Lung Cancer: A Review (2012) (123)
Constitutively Active Mitogen-activated Protein Kinase Kinase 6 (MKK6) or Salicylate Induces Spontaneous 3T3-L1 Adipogenesis* (1999) (123)
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. (2011) (122)
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. (2014) (121)
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care (2017) (119)
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer (2015) (118)
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). (2011) (118)
PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. (2019) (113)
Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer (2014) (112)
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. (2013) (111)
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer (2019) (111)
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer (2015) (110)
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer (2017) (106)
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer (2015) (104)
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. (2016) (103)
Activation of PI3K Signaling in Merkel Cell Carcinoma (2012) (103)
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. (2018) (102)
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. (2013) (100)
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3 (2010) (100)
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. (2012) (99)
OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab (2011) (98)
Programmed Cell Death Ligand (PD‐L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases (2017) (97)
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination (2016) (95)
MET Exon 14 Skipping in Non-Small Cell Lung Cancer. (2016) (95)
The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors (2006) (90)
Clinical Activity of Alectinib in Advanced RET‐Rearranged Non–Small Cell Lung Cancer (2016) (89)
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes (2017) (87)
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. (2016) (86)
Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists (2009) (86)
EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers (2011) (86)
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation (2017) (80)
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment (2016) (79)
TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts (2020) (76)
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. (2014) (75)
Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. (2013) (75)
Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer (2013) (74)
Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC (2008) (74)
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer (2010) (74)
Cyclin D- and E-Dependent Kinases and the p57KIP2 Inhibitor: Cooperative Interactions In Vivo (1999) (73)
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. (2016) (73)
Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. (2000) (71)
Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies (2016) (70)
Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. (2011) (70)
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. (2010) (69)
A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). (2010) (66)
Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). (2013) (64)
Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2 (2013) (64)
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM (2017) (62)
Apoptosis in targeted therapy responses: the role of BIM. (2012) (61)
AACR Cancer Progress Report 2014 (2014) (60)
Chemoprevention Meets Glucose Control (2010) (59)
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. (2016) (59)
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors (2019) (55)
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. (2021) (53)
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. (2016) (53)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (51)
Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance (2013) (51)
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents (2006) (49)
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling (2020) (48)
Modeling oncogene addiction using RNA interference (2008) (47)
PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). (2010) (45)
A sweet new role for EGFR in cancer. (2008) (44)
Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment (2018) (43)
Differences underlying EGFR and HER2 oncogene addiction (2010) (43)
Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. (2016) (43)
Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors (2014) (42)
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways (2015) (39)
The Allelic Context of the C 797 S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity toSubsequent Treatment Strategies (2015) (38)
The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer (2007) (36)
Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). (2015) (36)
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma (2018) (35)
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2 (2016) (35)
PI3K Charges Ahead (2007) (34)
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. (2017) (32)
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity (2019) (31)
Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. (2015) (30)
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers (2017) (29)
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer (2017) (29)
The present and future of PI3K inhibitors for cancer therapy (2021) (29)
EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer. (2010) (26)
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers (2019) (25)
Toward noninvasive genomic screening of lung cancer patients. (2009) (24)
A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. (2010) (24)
Factors predicting response to EGFR tyrosine kinase inhibitors. (2005) (24)
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. (2018) (22)
Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF/EGFR inhibitor ZD6474 (2005) (22)
Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers (2014) (21)
PIKing the Right Patient (2010) (20)
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms (2021) (20)
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR (2020) (19)
Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions. (2015) (19)
Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer (2021) (18)
Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy (2014) (17)
Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib. (2016) (17)
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer (2017) (16)
Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. (2011) (15)
Non-small cell lung cancer, locally advanced (2012) (15)
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors (2020) (15)
The double life of p85. (2014) (15)
Biochemistry. PI3K charges ahead. (2007) (13)
A new BATTLE in the evolving war on cancer. (2011) (12)
552 POSTER Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design (2008) (12)
Activation of PI 3 K Signaling in Merkel Cell Carcinoma (2012) (11)
Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer. (2010) (11)
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference (2007) (11)
Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib (2012) (11)
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263 (2018) (11)
High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. (2017) (10)
Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer. (2016) (10)
9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC) (2011) (9)
Genomics of Drug Sensitivity in Cancer (GDSC): A resource for biomarker discovery in cancer cells (2016) (9)
Abstract 5593: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers (2012) (9)
Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy. (2014) (9)
[18F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study (2015) (8)
Abstract 7: LKB1 deficiency is associated with a unique metabolic signature in Kras mutant non-small cell lung cancer (NSCLC) (2016) (8)
APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer (2021) (8)
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts (2020) (8)
Crizotinib Resensitization by Compound Mutation. (2016) (7)
Genotyping lung cancer is an investment in the future. (2014) (7)
PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis. (2017) (7)
Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression. (2015) (7)
Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy. (2011) (7)
SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. (2011) (7)
Acquired resistance to crizotinib from a mutation in CD74-ROS1. (2013) (6)
Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC). (2011) (6)
In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling (2019) (6)
Geldanamycins Chaperone and Are Destabilized following Exposure to Domain Mutations Associate with the Heat Shock Protein 90 Epidermal Growth Factor Receptors Harboring Kinase (2005) (6)
Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). (2014) (6)
Tumor and Stem Cell Biology STAT 3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis (2011) (6)
Lung Cancer by Activating ERBB3 Signaling Amplification Leads to Gefitinib Resistance in MET (2007) (5)
OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D (2017) (5)
Distinct evolutionary paths to TKI resistance in NSCLC (2018) (5)
Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC (2017) (5)
Cancer Therapy : Preclinical Human Breast Cancer Cells Harboring a Gatekeeper T 798 M Mutation in HER 2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER 2 (2013) (5)
Abstract B103: Integrative genomic and proteomic analyses identify novel targets for Lkb1 deficient metastatic lung tumors (2009) (4)
Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer (2017) (4)
Abstract 919: AZD3463, a novel ALK/IGF1R inhibitor, overcomes multiple mechanisms of acquired resistance to crizotinib. (2013) (4)
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. (2023) (4)
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbBLigands and Remain Dependent on the ErbBReceptor Network (2007) (4)
Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models (2013) (4)
Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. (2017) (4)
Relationship of EGFR-independent activation of PI3K in KRAS wild-type colorectal cancers and cetuximab resistance. (2013) (3)
SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). (2010) (3)
ConcomitantBRAFandPI3K/mTORBlockadeIsRequiredfor Effective Treatment of BRAF V600E Colorectal Cancer (2013) (3)
Clinicopathological characteristics of squamous cell carcinoma of the lung with programmed cell death ligand 1 (PD-L1) protein expression. (2015) (3)
In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC). (2010) (3)
Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors (2017) (3)
Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. (2013) (3)
Abstract S4-04: Overcoming resistance to PI3K inhibitors in PIK3CA mutant breast cancer using CDK4/6 inhibition: Results from a combinatorial drug screen (2013) (3)
Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747) (2018) (2)
Relationship of incomplete inhibition of PI3K pathway signaling and efficacy of cetuximab in KRAS wild-type colorectal cancers. (2012) (2)
The challenges of repeat biopsies at acquired resistance to EGFR TKIs. (2016) (2)
Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma. (2013) (2)
Abstract 3: HER2 gene-amplified human breast cancer cells harboring a gatekeeper T768M mutation in HER2 overexpress EGFR ligands and are sensitive to dual therapeutic blockade of EGFR and HER2 (2012) (2)
A landscape of synergistic drug combinations in non-small-cell lung cancer (2021) (2)
Abstract 957: The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer (2014) (2)
Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors (2009) (2)
Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma. (2015) (2)
Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib (2012) (2)
Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers (2018) (2)
PD-142 ErbB-3 mediates PI3K activity in gefitinib-sensitive non-smallcell lung cancer cell lines (2005) (1)
Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib (2017) (1)
149 Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS-mutant Cancer Models (2012) (1)
Predictive Biomarkers and Personalized Medicine ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1 , 683 Patients with Non – Small Cell Lung Cancer (2013) (1)
A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). (2011) (1)
Transformation from NSCLC to SCLC: when did it happen? - Authors' reply. (2015) (1)
Abstract 101: Adaptive feedback reactivates MAPK signaling in KRAS-mutant cancers with inhibition of MEK, but not ERK (2017) (1)
Abstract 3590: Resistance mechanisms to ALK inhibitors (2015) (1)
C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines. (2007) (1)
Abstract P3-12-03: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. (2012) (1)
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum. (2010) (1)
Corrigendum: EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers (Nature Medicine, (2012), 18, 1, (74-82), 10.1038/nm.2577) (2014) (1)
D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors (2007) (1)
Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation (2017) (1)
EGF816, an irreversible mutant-selective EGFR inhibitor, is effective in NSCLC with both primary activating and T790M-mediated resistant EGFR mutations (2016) (1)
Retraction Note: EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers (2022) (1)
Multiplex Genetic Analysis In Lung Cancer Using Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (2012) (1)
Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. (2016) (1)
A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC). (2013) (1)
Oncogenic in Mammary Epithelial Cells Mutations Are PIK 3 CA Associated − Breast Cancer (2005) (1)
Abstract 877: Evolution of resistance to EGFR inhibition from drug tolerant cancer cells (2016) (1)
Abstract A29: PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. (2013) (1)
Inhibition of PI3K–AKT signaling precludes endometrial cancer growth in a primary human xenograft model harboring an oncogenic PIK3CA mutation (2012) (1)
Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer) (2010) (1)
Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients (2015) (1)
Abstract 50: Anchored multiplex PCR for detection of gene rearrangements and mutations using next-generation sequencing. (2013) (1)
Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations (2015) (1)
Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer (2020) (1)
Abstract A13: Development of a drug response assessment platform for biopsy-derived tumor models (2016) (0)
Novel Therapeutic Approaches in Small Cell Lung Carcinoma Using Genetically Engineered Mouse Models and Human Circulating Tumor Cells (2016) (0)
Abstract B186: The unexpected role of p110β in HER2 amplified and PIK3CA mutant breast cancers. (2013) (0)
In Vivo Interactions p57 KIP2 Inhibitor: Cooperative Cyclin D- and E-Dependent Kinases and the (2013) (0)
Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. (2013) (0)
Abstract B53: Dynamic evolution of resistance to EGFR blockade from drug tolerant cancer cells (2015) (0)
Elkabets-Mutant Breast Cancer PIK 3 CA Inhibitors in α mTORC 1 Inhibition Is Required for Sensitivity to PI 3 K p 110 (2013) (0)
Methods of treating cancer resistant to ErbB doctor mites (2008) (0)
Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers (2011) (0)
Abstract 741: Combined inhibition of MDM2 and MEK for KRAS mutant non-small cell lung cancer (2014) (0)
Abstract PO-100: Expressed molecular barcoding coupled with single cell RNAseq enables a high resolution investigation into the evolution of drug tolerance (2020) (0)
647 Investigation of Role of Different PI3K Isoforms in Breast Cancer (2012) (0)
Cancer Therapy : Preclinical Concomitant BRAFandPI 3 K / mTORBlockade IsRequired for Effective Treatment of BRAFV 600 E Colorectal Cancer (2013) (0)
Abstract LB-259: FGFR- and EGFR-driven SHP2 activation displays differential sensitivity to allosteric SHP2 inhibition (2019) (0)
Abstract 5121: A targeted approach to identify activators of class IA phosphoinositide-3-kinase in cancers using tandem mass spectrometry (2011) (0)
Abstract 2210: Activation of PI3K in Merkel cell carcinoma (2011) (0)
Abstract 4465: Concurrent roles for IGF1R and EGFR in driving acquired resistance to crizotinib and ability to overcome with a combination of the ALK/IGF1R inhibitor AZD3463 and Iressa. (2013) (0)
Abstract 299: Patient-derived tumor microenvironment models uncover non-autonomous TKI resistance mechanisms in NSCLC (2016) (0)
Abrogates Anchorage-independent Growth Oncogenically Transformed Cells Recombinant Expression of Caveolin-1 in CELL BIOLOGY AND METABOLISM: (2014) (0)
Author response: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways (2015) (0)
Abstract A062: Sensitizing low BIM expressing breast cancers to targeted therapies (2013) (0)
amplification of C RKL ind uces t ra nsformation and epi dermal Growth Factor r ec eptor inh ibitor r es istance in hum an Non- s ma ll cel l lun g can cers (2011) (0)
Multimodal imaging of lung cancer and its microenvironment (Conference Presentation) (2016) (0)
Abstract 291: Single cell analyses reveal resistance heterogeneity in EGFR mutant NSCLC (2016) (0)
8 Combination Therapy Approaches for KRAS Mutant Cancers (2012) (0)
Abstract 4648: Uncover novel drug combinations for triple negative breast cancer (2016) (0)
Rociletinib-associated cataracts in EGFR-mutant NSCLC. (2016) (0)
Abstract 2845: Co-acquisition of T790M and EMT in resistant EGFR mutant non-small cell lung cancer can be overcome by combined irreversible EGFR and BCL-XL inhibition (2015) (0)
Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors (2019) (0)
Abstract 1137: Expression of specific apoptotic mediators predicts sensitivity to combined MEK and PI3K inhibition in KRAS mutant non-small cell lung cancer according to TP53 mutational status. (2013) (0)
EGFR species with kinase domain activating mutations interact with the Hsp90 chaperone and are sensitive to degradation following exposure to Geldanamycin (2005) (0)
O-009 Differential effects of gefitinib and cetuximab on EGFR mutant non-small cell lung cancers (NSCLC) cell lines (2005) (0)
ALK Resistance Mutations in ALK-Positive Lung Cancer (2016) (0)
Abstract 1053: A large cellular screen charting the landscape of synergistic drug combinations in lung cancer (2021) (0)
Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer (2021) (0)
Abstract 2933: Assessment of ABT-263 activity across a comprehensive cancer cell line collection leads to a novel, potent combination therapy for small cell lung cancer (2014) (0)
Abstract A22: Detection of PD-L1 and lymphocytes infiltration in Juvenile Recurrent Respiratory Papillomatosis (JRRP) (2017) (0)
Methods for treating cancer resistant to ErbB therapeutics (2008) (0)
Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (0)
Abstract 2038: Establishment and analysis of an in vitro model for hemangioblastomas of the central nervous system (2014) (0)
Abstract A48: Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice (2016) (0)
Koyama et al-2016-Nat Commun - supplement (2016) (0)
Author response: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer (2017) (0)
Integrated Systems and Technologies Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI 3 K in Cancer (2011) (0)
Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. (2011) (0)
428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations (2014) (0)
Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. (2013) (0)
Abstract 3135: Pre-treatment p-EGFR levels in tumors from a genetically engineered mouse model of BRAFV600E colorectal cancer predict response to combined BRAF/EGFR inhibition (2014) (0)
Abstract PR04: Decoding tumor microenvironment to enhance NSCLC targeted therapy (2018) (0)
A Functional Landscape o f Resistance to ALK Inhibition in Lung Cancer Graphical Abstract Highlights (2015) (0)
Abstract A145: SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC (2018) (0)
Abstract 4348: Antitumor activity of Tivantinib (ARQ 197) is due to inhibition of tubulin polymerization in addition to c-Met inhibition. (2013) (0)
Abstract 4773: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways (2014) (0)
Depression and EGFR mutation status in stage IV non-small cell lung cancer. (2010) (0)
An Instrumental and Software Platform for The Targeted Protein-Protein Interact-ome of Signaling Pathways from Drosophila to Human Cancer Cells (2010) (0)
Developing Novel Therapeutic Approaches in Small Cell Lung Carcinoma Using Genetically Engineered Mouse Models and Human Circulating Tumor Cells (2015) (0)
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. (2023) (0)
Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms (2013) (0)
Methods of treating resistant cancer therapeutic agents ERBB (2008) (0)
Abstract 4184: Pre-clinical study using KRAS mutant mouse models for lung cancer immunotherapy together with MEK inhibition (2016) (0)
Figure 2—source data 1. (2015) (0)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia (2018) (0)
PROTEIN COMPLEXES ’98 Molecular Genetics of the Caveolin Gene Family: Implications for Human Cancers, Diabetes, Alzheimer Disease, and Muscular Dystrophy (1998) (0)
Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition (2020) (0)
am plification of CRKL in duces t r ansformation and ep idermal Growth Factor r e ceptor in hibitor r e sistance in hu man Non- s m all ce ll lu ng ca ncers (2011) (0)
Science Translational Medicine Podcast: 8 February 2012 (2012) (0)
Abstract 2446: Real-time molecular imaging of targeted therapies in patient-derived tumor cells by quantitative immunofluorescence microscopy (2012) (0)
Abstract A142: Targeting FGFR to overcome EMT-related resistance in EGFR-mutated non-small cell lung cancer (2018) (0)
Abstract PR06: Overcoming resistance to PI3K inhibitors in breast cancer: Results of a pooled shRNA screen and combinatorial drug screen (2013) (0)
Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling (2012) (0)
Part 1: Targeting cancer pathways: Tumor resistance (2014) (0)
Identification of differentially regulated gene targets in the Myc and Mad family proteins (1999) (0)
Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint (2015) (0)
Abstract 394:In vivoshRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies forBRAF-mutant colorectal cancer (2019) (0)
Abstract 394: In vivo shRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies for BRAF-mutant colorectal cancer (2019) (0)
Exon 9 and exon 20 mutations inPIK3CAconfer resistance to HER2 inhibitors in HER2-overexpressing breast cancer cells. (2009) (0)
Abstract 4954: Decoding tumor microenvironment to enhance NSCLC targeted therapy (2018) (0)
Abstract A87: Overcoming NSCLC to SCLC transformation as a resistance mechanism in EGFR mutant lung cancer. (2013) (0)
Therapeutics , Targets , and Chemical Biology Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Ef fi cacy of Combined MEK and PI 3 K Inhibitors for KRAS-Mutant Lung Cancers (2014) (0)
MC13-0075 Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients (2013) (0)
Abstract 2619: Meausuring PIP3 reveals the unexpected role of p110B in luminal breast cancers (2014) (0)
Abstract 5502: Characterization of a hotspotPTENmutation in endometrial cancer (2018) (0)
O-028: CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE ROS1 GENE REARRANGEMENT (2012) (0)
Abstract 3715: Discovery of novel targets for effective combination drug therapy in ALK+ NSCLC patient derived models of acquired resistance (2014) (0)
Figure 5—source data 2. (2015) (0)
Disparate effects of gefitinib and lapatinib on egfr mutant lung cancer (2008) (0)
Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers (2015) (0)
Abstract 875: Markedin vivoefficacy of combined BCLXL and MEK inhibition in KRAS mutant cancers revealed by a pooled shRNA-drug screen for genes that are “synthetically lethal” with MEK inhibitors (2012) (0)
PD-0004DIFFERENT SUBSETS OF BRAF MUTANT COLORECTAL CANCERS EXHIBIT EGFR-DEPENDENT AND INDEPENDENT RESISTANCE TO RAF INHIBITOR THERAPY (2013) (0)
Abstract 955: Transformation from NSCLC to SCLC in EGFR mutant lung cancers with acquired resistance to EGFR inhibitors (2014) (0)
Abstract A13: Functional genomic analysis of central nervous system hemangioblastomas (2015) (0)
Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts (2020) (0)
Abstract A44: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors (2019) (0)
Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC) (2017) (0)
Abstract A122: Molecular barcoding and single cell approaches to investigate drug tolerance in EGFRmutNSCLC (2019) (0)
From the editors (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jeffrey A. Engelman?

Jeffrey A. Engelman is affiliated with the following schools:

KU Leuven
Albert Einstein College of Medicine
University of Tokyo
Nagoya City University
Massachusetts General Hospital